Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancerPierFranco Conte, Valentina Guarneri, Antonio Frassoldati et al.|Annals of Oncology|2017Cited by 4